Literature DB >> 17658910

Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

Francis Blotman1, Bernard Cortet, Pascal Hilliquin, Bernard Avouac, François-André Allaert, Denis Pouchain, Anne-Françoise Gaudin, François-Emery Cotté, Abdelkader El Hasnaoui.   

Abstract

BACKGROUND: The public health burden of osteoporosis is high, principally because of increased risk of fractures and associated morbidity, handicap and mortality. Osteoporotic fracture prevention is therefore an important public health goal. General practitioners (GPs) play a key role in the management of osteoporosis, both in ensuring timely diagnosis and in providing treatment. Little information is available on standards of care for postmenopausal women with osteoporosis in general practice.
OBJECTIVES: The primary objective of this study was to describe risk factors and treatment in postmenopausal women with osteoporosis. Secondary objectives were to evaluate treatment compliance and to assess the impact of osteoporosis on quality of life.
METHODS: This observational, cross-sectional, pharmacoepidemiological study was performed in a primary-care setting in France. A random sample of GPs recruited postmenopausal women with a diagnosis of osteoporosis who had been followed by the investigator for at least 2 years. At inclusion, investigators completed a questionnaire providing information on patient age, osteoporosis duration, risk factors and treatment history. The first three patients recruited by each investigator completed a questionnaire providing information on sociodemographic features, osteoporosis treatments and quality of life. Treatment compliance was quantified using the Test d'Evaluation de l'Observance and quality of life evaluated using the 12-item Short Form Health Survey (SF-12).
RESULTS: Overall, 389 physicians included 3,097 patients, of whom 1,053 completed the patient questionnaire. Risk factors for osteoporotic fracture were identified in 2,148 patients (69.4%), most frequently personal or maternal antecedents of osteoporotic fracture and a low body mass index. Of these, 946 (44.0%) presented more than one risk factor. At the time of diagnosis, 629 patients (59.7%) presented fractures, which involved the vertebrae in 51.7% of cases, the wrist in 40.5% and the hip in 5.4%. Older patients were more likely to have fractures at the time of diagnosis and to have multiple fractures. After diagnosis, at least one new fracture occurred in 201 patients (19.2%). Multivariate logistic regression analysis identified age >70 years, diagnosis at least 10 years previously, diagnosis based on the presence of a fracture, biochemical and haematological evaluation at the time of diagnosis, and a change in osteoporosis treatment in the previous 2 years as being significantly associated with incident fracture risk. At inclusion, 1,019 patients (97.4%) were receiving treatment for osteoporosis, most frequently weekly bisphosphonates (71.6% of treatments). Most patients (81.0%) had been treated for at least 1 year. Treatment compliance was high in 61% of patients and low in <5%. Patient variables associated with high compliance were being retired, prescription of bisphosphonates and, among the bisphosphonate users, prescription of weekly formulations. SF-12 quality-of-life scores were low, ranging from 38.6 (energy/vitality) to 65.1 (social functioning) out of a possible maximum score of 100. Baseline variables associated with SF-12 physical component summary scores included age, height loss since menopause, diagnosis following a fracture, fracture incidence since diagnosis, time since diagnosis and treatment with bisphosphonates.
CONCLUSIONS: In this study of postmenopausal osteoporosis in the French primary healthcare setting, many women with osteoporosis were diagnosed following a fracture. Although most were treated with bone-consolidating drugs, compliance was suboptimal in a significant minority. Osteoporotic fracture was associated with reduced quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 17658910     DOI: 10.2165/00002512-200724070-00007

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  59 in total

Review 1.  Prescreening tools to determine who needs DXA.

Authors:  Elliott N Schwartz; Dee M Steinberg
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

2.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

3.  Residential status and risk of hip fracture.

Authors:  R Norton; A J Campbell; I R Reid; M Butler; R Currie; E Robinson; H Gray
Journal:  Age Ageing       Date:  1999-03       Impact factor: 10.668

4.  Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

Authors:  Mark P Ettinger; Rich Gallagher; Paul E MacCosbe
Journal:  Endocr Pract       Date:  2006 Sep-Oct       Impact factor: 3.443

5.  The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.

Authors:  Joyce A Cramer; Niall O Lynch; Anne-Francoise Gaudin; Mel Walker; Warren Cowell
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

6.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

7.  The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population.

Authors:  M Naves; J B Díaz-López; C Gómez; A Rodríguez-Rebollar; M Rodríguez-García; J B Cannata-Andía
Journal:  Osteoporos Int       Date:  2003-04-25       Impact factor: 4.507

8.  Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff.

Authors:  Julieann Brennan nee Saunders; Antony Johansen; John Butler; Mike Stone; Peter Richmond; Sarah Jones; Ronan A Lyons
Journal:  Osteoporos Int       Date:  2003-04-30       Impact factor: 4.507

9.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

10.  International variations in hip fracture probabilities: implications for risk assessment.

Authors:  John A Kanis; Olof Johnell; Chris De Laet; Bengt Jonsson; Anders Oden; Alan K Ogelsby
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

View more
  8 in total

Review 1.  A systematic review of factors affecting medication adherence among patients with osteoporosis.

Authors:  C T Yeam; S Chia; H C C Tan; Y H Kwan; W Fong; J J B Seng
Journal:  Osteoporos Int       Date:  2018-11-12       Impact factor: 4.507

2.  A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years.

Authors:  M Audran; F J Jakob; S Palacios; M-L Brandi; H Bröll; N A T Hamdy; E V McCloskey
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

3.  Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.

Authors:  E W de Bekker-Grob; M L Essink-Bot; W J Meerding; H A P Pols; B W Koes; E W Steyerberg
Journal:  Osteoporos Int       Date:  2008-01-08       Impact factor: 4.507

4.  MENOPOST--calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study.

Authors:  A Reymondier; P Caillet; F Abbas-Chorfa; V Ambrosi; S B Jaglal; R Chapurlat; A-M Schott
Journal:  Osteoporos Int       Date:  2012-05-16       Impact factor: 4.507

5.  Management of osteoporosis and associated quality of life in post menopausal women.

Authors:  Bernard Cortet; Francis Blotman; Françoise Debiais; Dominique Huas; Florence Mercier; Chantal Rousseaux; Véronique Berger; Anne-Françoise Gaudin; François-Emery Cotté
Journal:  BMC Musculoskelet Disord       Date:  2011-01-12       Impact factor: 2.362

6.  Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France.

Authors:  François-Emery Cotté; Gérard De Pouvourville
Journal:  BMC Health Serv Res       Date:  2011-06-25       Impact factor: 2.655

7.  Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.

Authors:  Bernard Cortet; Ankita Modi; Jackson Tang; Chun-Po Steve Fan; Shiva Sajjan; Jessica Papadopoulos Weaver
Journal:  BMC Musculoskelet Disord       Date:  2016-04-30       Impact factor: 2.362

8.  The Prevalence of Osteopenia and Osteoporosis Among Malaysian Type 2 Diabetic Patients Using Quantitative Ultrasound Densitometer.

Authors:  Shaymaa Abdalwahed Abdulameer; Mohanad Naji Sahib; Syed Azhar Syed Sulaiman
Journal:  Open Rheumatol J       Date:  2018-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.